resimmune
Resimmune or A-dmDT390-bisFv(UCHT1) is an experimental drug — an anti-T cell immunotoxin — that is being investigated for the treatment of T cell blood cancers such as cutaneous T cell lymphoma (CTCL). It was developed by Doctors Neville, Woo, and Liu while at the National Institutes of Health (NIH) and is under exclusive license to Angimmune, LLC. The therapy has potential applications for lymphomas and T cell driven autoimmune diseases, including multiple sclerosis, and graft-versus-host disease following stem cell or bone marrow transplant. — Wikipedia
Clinical trial activity
4 trials · 21 clinical orgs · 0 marketing orgs
Earliest trial started Jan 1, 2008 (NCT00611208)
Timeline
Indications
Mechanism of action
CD3E activator
- T-cell surface glycoprotein CD3 epsilon chainBINDING AGENT
T-cell surface glycoprotein CD3 epsilon chain binding agent
- Elongation factor 2INHIBITOR
Elongation factor 2 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- diphtheria toxin
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaResimmune ↗
- ChEMBLCHEMBL4297555 ↗
Also known as
- resimmune
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02943642 | Phase 2 | Jan 1, 2017 | Angimmune LLC, City of Hope National Medical Center, Columbia University, Harvard University, Hoosier Cancer Research Network, Northwestern University, Ohio State University, Rush University, Scott and White Healthcare, Stanford University, The University of Texas, Dallas, Thomas Jefferson University, University of Colorado, Denver, University of South Florida, University of Washington, Vanderbilt University, Washington University in St. Louis, Yale University |
| NCT02990416 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2017 | Angimmune LLC, James Graham Brown Cancer Center, University of Louisville |
| NCT01888081 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2014 | Angimmune LLC, University of Louisville |
| NCT00611208 | Phase 2 | Jan 1, 2008 | Angimmune LLC, James Graham Brown Cancer Center, Scott and White Healthcare, The University of Texas, Dallas, University of Texas at Houston, Yale University |
Organizations
Research & Development (21)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Angimmune LLC | For profit | 4 | 4 | 1 | 2008 |
| James Graham Brown Cancer Center | Academic/Hospital | 2 | 0 | 1 | 2008 |
| Scott and White Healthcare | Academic/Hospital | 2 | 0 | 1 | 2008 |
| The University of Texas, Dallas | Academic/Hospital | 2 | 0 | 1 | 2008 |
| University of Louisville | Academic/Hospital | 2 | 0 | 1 | 2014 |
| Yale University | Academic/Hospital | 2 | 0 | 1 | 2008 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Hoosier Cancer Research Network | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Northwestern University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Rush University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Thomas Jefferson University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of South Florida | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 2017 |